2017
DOI: 10.1093/ecco-jcc/jjx002.787
|View full text |Cite
|
Sign up to set email alerts
|

P663 Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study

Abstract: Background:The infliximab biosimilar CT-P13 is EMA and FDA approved, based on data extrapolated from phase III studies in rheumatoid arthritis and ankylosing spondylitis patients. Anti-tumor necrosis factor (TNF) naive IBD patients frequently start CT-P13 in current daily practice but the switch from Remicade ® to CT-P13 is less

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance